Medtronic 2015 Annual Report Download - page 12

Download and view the complete annual report

Please find page 12 of the 2015 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 166

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166

Minimally Invasive Therapies Group (Fiscal year 2015 net sales of $2.387 billion)
•Surgical Solutions
•Patient Monitoring and Recovery
Restorative Therapies Group (Fiscal year 2015 net sales of $6.751 billion)
•Spine
•Neuromodulation
•Surgical Technologies
•Neurovascular
Diabetes Group (Fiscal year 2015 net sales of $1.762 billion)
•Intensive Insulin Management
•Non-Intensive Diabetes Therapies
•Diabetes Services & Solutions
CARDIAC AND VASCULAR GROUP
Cardiac Rhythm & Heart Failure Disease Management (CRHF)
Our CRHF division develops, manufactures, and markets products for the diagnosis, treatment, and management of heart
rhythm disorders and heart failure. Our products include implantable devices, leads and delivery systems, products for the
treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the
management of patients with CRHF devices, and an integrated health solutions business.
The following are the principal products and services offered by our CRHF division:
Implantable Cardiac Pacemakers (Pacemakers) Our latest generation of pacemaker systems is the Advisa and Revo MRI
SureScan models, which have received United States (U.S.) Food and Drug Administration (U.S. FDA) approval, and the
Advisa and Ensura MRI SureScan models as well as the Micra Transcatheter Pacing System, which have all received
Conformité Européene (CE) Mark approval.
Implantable Cardioverter Defibrillators (ICDs) Our latest generation ICD is the Evera MRI SureScan, the first ICD system
with CE Mark approval for full-body MRI scans. The Evera system is paired with the reliable Sprint Quattro Secure lead, the
only defibrillator lead with more than 10 years of proven performance with active monitoring.
Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps) Our latest generation of CRT-Ds is the
Viva/Brava family with Attain Performa quadripolar lead and features a new algorithm, called AdaptivCRT, which improves
heart failure patients’ response rate to CRT-D therapy. With respect to CRT-P, Viva CRT-P is our latest generation device.
AF Products Our portfolio of AF products includes the Arctic Front Advance Cardiac Cryoballoon System designed for
pulmonary vein isolation in the treatment of patients with drug refractory paroxysmal AF. Additionally, we have a second-
generation CE Mark approved Phased RF System, PVAC Gold, which uses duty cycled, phased radio frequency energy for the
treatment of symptomatic paroxysmal persistent and long-standing persistent AF.
Diagnostics and Monitoring Devices Our Reveal LINQ is our newest Insertable Cardiac Monitor (ICM) System. The system
is used to record the heart’s electrical activity before, during, and after transient symptoms such as syncope (i.e., fainting) and
palpitations to assist in diagnosis.
Services and Solutions Our Cardiocom products and services include remote monitoring and patient-centered software to
enable efficient care coordination and specialized telehealth nurse support. Our TYRX products include the Absorbable
Antibacterial Envelope and the TYRX Neuro Absorbable Antibacterial Envelope, which are designed to stabilize electronic
implantable devices and help prevent infection associated with implantable pacemakers, defibrillators, and spinal cord
neurostimulators. Our Cath Lab Managed Services business is focused on developing novel partnerships with hospitals to
provide services directly related to hospital operational efficiency.
Coronary & Structural Heart Disease Management (CSH)
Our CSH division includes therapies to treat coronary artery disease (CAD), and heart valve disorders. Our products include
coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guide
wires, diagnostic catheters, and accessories as well as products for the repair and replacement of heart valves, perfusion systems,
positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products.
2